Who should get lung cancer screening?

USPSTF 2021: Age 50-80, ≥20 pack-years, current or quit ≤15 years. Annual LDCT.

Pack-years = (packs per day) × (years smoked). 1 pack/day for 20 years = 20 pack-years.

Does screening reduce mortality?

NLST showed ~20% reduction in lung cancer mortality with annual LDCT in high-risk individuals.

What if I quit smoking?

Risk decreases over time. After 15 years quit, screening may not be recommended per USPSTF.

5 more

MEDICALPulmonaryHealth Calculator

🫁

Lung Cancer Risk Assessment

Pack-years, age, family history, COPD. USPSTF: Age 50-80, ≥20 pack-years, current or quit ≤15 years.

Did our AI summary help? Let us know.

80-90% linked to smoking LDCT screening saves lives Quit smoking reduces risk

Ready to run the numbers?

Why: Early detection via LDCT reduces mortality by ~20% in high-risk individuals.

How: Risk based on smoking pack-years, age, family history, COPD, and occupational exposures.

80-90% linked to smokingLDCT screening saves lives

Sources:USPSTF 2021

Run the calculator when you are ready.

Assess Your RiskUse the calculator below to check your health metrics

Low Risk - Never Smoker

Non-smoker with no risk factors

Click to load

Moderate - Former Smoker

Former smoker meeting screening criteria

Click to load

High Risk - Current Smoker

Current heavy smoker

Click to load

Very High Risk

Multiple risk factors present

Click to load

LDCT Screening Eligible

Meets USPSTF screening criteria

Click to load

Sample Scenarios

Low Risk - Never Smoker

Non-smoker with no risk factors

Moderate - Former Smoker

Former smoker meeting screening criteria

High Risk - Current Smoker

Current heavy smoker

Very High Risk

Multiple risk factors present

LDCT Screening Eligible

Meets USPSTF screening criteria

Enter Risk Factors

Demographics

Age (years)

Gender

BMI

Smoking

Smoking Status

Pack-Years

Years Since Quit

History

Family History of Lung Cancer

COPD/Emphysema

Prior Cancer

Exposures

Asbestos Exposure

Radon Exposure

For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.

🏥 Health Facts

⚠️

Smoking cessation is the most effective prevention.

— CDC

Lung Cancer Risk Factors

Lung cancer is the leading cause of cancer death worldwide. Smoking is responsible for 80-90% of lung cancer cases. Other risk factors include family history, occupational exposures, and COPD. Early detection through screening can reduce mortality by 20% in high-risk individuals.

Smoking

80-90% of lung cancers. Risk increases with pack-years.

Occupational

Asbestos, radon, diesel exhaust, heavy metals.

Medical History

COPD, prior cancer, family history.

Understanding Lung Cancer Risk

Lung cancer is the leading cause of cancer death worldwide. Risk assessment helps identify high-risk individuals who may benefit from screening with low-dose CT (LDCT). Early detection significantly improves survival rates.

#1 Cancer Killer

Leading cause of cancer death

~85%

Cases linked to smoking

20%

Mortality reduction with LDCT screening

Major Risk Factors

Modifiable

• Cigarette smoking (primary cause)
• Secondhand smoke exposure
• Occupational exposures (asbestos, radon)
• Air pollution
• Diet and physical activity

Non-Modifiable

• Age (risk increases with age)
• Family history of lung cancer
• Personal history of lung disease
• Prior radiation to chest
• Genetic predisposition

Understanding Pack-Years

• Formula: Pack-years = (Packs per day) × (Years smoked)
• 1 pack: 20 cigarettes
• Example: 1 pack/day for 30 years = 30 pack-years
• Example: 2 packs/day for 15 years = 30 pack-years
• Screening threshold: ≥20-30 pack-years typically qualifies
• Risk increase: Linear relationship with lung cancer risk

LDCT Screening Eligibility (USPSTF 2021)

• Age: 50-80 years
• Smoking history: ≥20 pack-years
• Current smoker: OR quit within past 15 years
• General health: Able to undergo treatment if cancer found
• Frequency: Annual screening
• Stop screening when: >15 years since quit or develops condition limiting treatment

Clinical Pearls

💡NLST showed 20% reduction in lung cancer mortality with LDCT screening
💡Smoking cessation reduces risk but never reaches baseline of never-smokers
💡~10-15% of lung cancers occur in never-smokers
💡LDCT has high false-positive rate (~25%) - requires careful follow-up
💡Shared decision-making is essential before screening

Types of Lung Cancer

Non-Small Cell (NSCLC) - 85%

• Adenocarcinoma (most common)
• Squamous cell carcinoma
• Large cell carcinoma
• Generally slower growing
• Surgery possible in early stages

Small Cell (SCLC) - 15%

• Strongly associated with smoking
• Aggressive, rapid growth
• Often metastatic at diagnosis
• Responsive to chemo/radiation initially
• Worse prognosis overall

Warning Signs and Symptoms

Common Symptoms

• Persistent cough (new or worsening)
• Coughing up blood (hemoptysis)
• Shortness of breath
• Chest pain
• Hoarseness
• Unexplained weight loss

Concerning Features

• Symptoms in current/former smoker
• Persistent cough >3 weeks
• Recurrent respiratory infections
• Finger clubbing
• Bone pain (metastases)

Lung Cancer Prevention

• Quit smoking: Single most effective prevention strategy
• Avoid secondhand smoke: No safe level of exposure
• Test for radon: Second leading cause of lung cancer
• Workplace safety: Use PPE for asbestos/carcinogen exposure
• Healthy lifestyle: Diet rich in fruits/vegetables, regular exercise
• Screening: For high-risk individuals per guidelines

Lung Cancer Risk Quick Summary

Low Risk

Never smokers, no exposures

Screening not recommended

High Risk

≥20 pack-years, age 50-80

Annual LDCT screening recommended

The NLST Trial (2011)

• National Lung Screening Trial: Landmark study demonstrating LDCT efficacy
• Population: 53,454 high-risk individuals randomized to LDCT vs chest X-ray
• Eligibility: Age 55-74, ≥30 pack-years, current or quit <15 years
• Results: 20% reduction in lung cancer mortality with LDCT
• All-cause mortality: 6.7% reduction
• False positives: 24% had abnormal LDCT findings (most benign)

The NELSON Trial (2020)

• European study: Further confirmed LDCT screening benefit
• Mortality reduction: 24% in men, greater in women
• Volume-based assessment: Used nodule volumetry to reduce false positives
• Lung-RADS: Structured reporting system developed from NLST/NELSON data

Radon Exposure

About Radon

• Natural radioactive gas from soil uranium
• Second leading cause of lung cancer
• Can accumulate in homes/buildings
• Synergistic effect with smoking

Prevention

• Test home radon levels
• EPA action level: ≥4 pCi/L
• Mitigation systems available
• Seal basement cracks, improve ventilation

Occupational Exposures

Known Carcinogens

• Asbestos
• Arsenic
• Chromium compounds
• Nickel compounds
• Diesel exhaust
• Silica

High-Risk Occupations

• Mining (uranium, hard rock)
• Construction/shipyard workers
• Manufacturing
• Firefighters
• Painters
• Truck drivers

Smoking Cessation Benefits

• After 5 years: Risk drops by ~39%
• After 10 years: Risk about half that of current smoker
• After 15+ years: Risk continues to decline but never reaches baseline
• Never too late: Quitting at any age provides benefit
• Pharmacotherapy: NRT, varenicline, bupropion increase quit rates
• Behavioral support: Counseling doubles success rate

Lung-RADS Classification

Category	Finding	Action
1	Negative	Continue annual screening
2	Benign appearance	Continue annual screening
3	Probably benign	6-month follow-up LDCT
4A	Suspicious	3-month follow-up LDCT or PET-CT
4B/4X	Very suspicious	Tissue diagnosis recommended

Lung Cancer Staging Overview

Early Stage (I-II)

• Localized disease
• Often curable with surgery
• 5-year survival: 50-90%
• Goal of screening: Detect at this stage

Advanced Stage (III-IV)

• Regional or distant spread
• Surgery often not possible
• Chemo, radiation, immunotherapy
• 5-year survival: 5-30%

Lung Cancer in Never Smokers

• Prevalence: 10-15% of lung cancers in never smokers
• More common in: Women, Asian populations
• Histology: Predominantly adenocarcinoma
• Risk factors: Radon, secondhand smoke, air pollution, genetics
• Driver mutations: Higher rate of EGFR, ALK mutations (targetable)
• Screening: Not routinely recommended for never smokers (insufficient evidence)

Shared Decision-Making

Before LDCT screening, discuss with patients:

• Benefits: Early detection, mortality reduction
• Harms: False positives, radiation exposure, anxiety, overdiagnosis
• Follow-up: Abnormal findings may need additional imaging or biopsy
• Smoking cessation: Most effective intervention, offer support
• Commitment: Annual screening for ongoing benefit

Validated Risk Models

PLCOm2012

• Derived from PLCO trial
• Includes age, BMI, education, COPD
• Family history, smoking duration
• 6-year lung cancer risk prediction

LLP Model

• Liverpool Lung Project
• Includes pneumonia history
• Asbestos exposure
• Prior cancer diagnosis

Lung Cancer Statistics

• US cases: ~235,000 new cases annually
• US deaths: ~130,000 deaths annually
• 5-year survival (all stages): ~22%
• 5-year survival (localized): ~60%
• Median age at diagnosis: 70 years
• Smoking attributable: ~85% of cases

Clinical Scenario Examples

55-year-old, 40 pack-years, quit 5 years ago

High risk - Recommend annual LDCT screening and reinforce cessation success.

68-year-old, 25 pack-years, current smoker

High risk - Recommend LDCT screening AND smoking cessation counseling/pharmacotherapy.

45-year-old, never smoker, no exposures

Low risk - LDCT screening not recommended. Monitor for symptoms.

Potential Harms of LDCT Screening

• False positives: ~24% have abnormal findings (most benign)
• Additional procedures: Follow-up CT, PET-CT, biopsy
• Procedure complications: Pneumothorax, bleeding from biopsy
• Radiation exposure: Small but cumulative with annual scans
• Overdiagnosis: Detection of indolent tumors that may never cause harm
• Anxiety: From abnormal findings and waiting for results

Lung Cancer Treatment Overview

Surgery

• Lobectomy (standard for localized)
• Wedge resection (small tumors)
• Pneumonectomy (rare)
• VATS/robotic minimally invasive

Systemic Therapy

• Chemotherapy (platinum-based)
• Targeted therapy (EGFR, ALK, ROS1)
• Immunotherapy (checkpoint inhibitors)
• Combination regimens

Radiation

• SBRT for inoperable early stage
• Concurrent chemoradiation (stage III)
• Palliative (symptom control)
• Brain metastases

Supportive Care

• Pain management
• Pulmonary rehabilitation
• Nutrition support
• Palliative care integration

Targeted Therapy and Biomarkers

• EGFR mutations: Osimertinib, erlotinib (more common in never smokers)
• ALK rearrangements: Alectinib, lorlatinib
• ROS1 rearrangements: Crizotinib, entrectinib
• KRAS G12C: Sotorasib, adagrasib
• MET amplification: Capmatinib, tepotinib
• Testing: All advanced NSCLC should have comprehensive genomic profiling

Immunotherapy in Lung Cancer

Checkpoint Inhibitors

• Pembrolizumab (PD-1)
• Nivolumab (PD-1)
• Atezolizumab (PD-L1)
• Durvalumab (PD-L1)

PD-L1 Testing

• TPS ≥50%: Monotherapy option
• TPS 1-49%: Combination with chemo
• TPS <1%: Chemo +/- IO
• Higher PD-L1 often correlates with response

Pulmonary Nodule Evaluation

• Solid nodule <6mm: Usually no follow-up (low risk)
• Solid nodule 6-8mm: Follow-up CT at 6-12 months
• Solid nodule >8mm: Consider PET-CT, biopsy, or short-interval CT
• Ground-glass nodule: May be slower growing, follow-up intervals longer
• Spiculated, upper lobe: Higher malignancy risk
• Calcification patterns: Central, popcorn, laminated often benign

Surveillance After Lung Cancer Treatment

• History/physical: Every 3-6 months for 2 years, then annually
• CT chest: Every 6-12 months for surveillance
• Smoking cessation: Essential - reduces second primary risk
• Monitor for: Local recurrence, distant metastases, second primary
• Survivorship: Address long-term effects, QoL, psychosocial needs

When to Stop LDCT Screening

• Patient turns 81 years old
• Has not smoked for 15+ years
• Develops health condition limiting treatment or reducing life expectancy
• Unable or unwilling to undergo curative treatment if cancer found
• Patient choice after shared decision-making discussion

Key Formulas and Definitions

Pack-years: (Packs per day) × (Years smoked)
USPSTF Eligibility: Age 50-80 + ≥20 pack-years + current or quit ≤15 years
Number Needed to Screen (NNS): ~320 to prevent 1 lung cancer death
NLST Mortality Reduction: 20% relative risk reduction

Documentation for LDCT Screening

• Risk factors: Pack-years, years since quit, age
• Shared decision-making: Document discussion of benefits and harms
• Smoking cessation: Counseling provided, pharmacotherapy offered
• Eligibility confirmation: Meets USPSTF criteria
• Order: LDCT for lung cancer screening (specific code)
• Follow-up plan: Result tracking, next steps

Lung Cancer Risk Quick Facts

• Leading cancer killer: More deaths than breast, colon, prostate combined
• Smoking: Causes ~85% of cases
• Screening: LDCT reduces mortality by 20% in high-risk
• Early detection: Stage I 5-year survival ~60-90%
• Late detection: Stage IV 5-year survival ~5%
• Never too late: Quitting smoking always helps

Risk Assessment Summary

Age

50-80 years

Pack-Years

≥20

Quit

≤15 years ago

Screening

Annual LDCT

Family History and Genetic Risk

• First-degree relative: 1.5-2x increased risk
• Multiple affected relatives: Higher risk
• Young-onset in family: May suggest genetic component
• Li-Fraumeni syndrome: TP53 mutations increase lung cancer risk
• Genetic susceptibility: CHRNA3/5, TERT polymorphisms
• Gene-environment interaction: Genetic factors may modify smoking risk

COPD and Lung Cancer Connection

• Independent risk factor: COPD increases lung cancer risk even after adjusting for smoking
• Mechanism: Chronic inflammation, oxidative stress, shared genetic susceptibility
• Risk increase: 2-6x higher than smokers without COPD
• Screening implication: COPD patients warrant careful screening consideration
• Emphysema: CT-detected emphysema correlates with lung cancer risk

Air Pollution and Lung Cancer

• PM2.5: Fine particulate matter classified as Group 1 carcinogen
• Risk increase: ~10% per 10 μg/m³ increase in PM2.5
• Global burden: Responsible for ~5% of lung cancer deaths worldwide
• Urban vs rural: Higher rates in areas with more pollution
• Reduction strategies: Clean air policies, masks, air purifiers

Symptoms by Disease Stage

Early Stage (Often Asymptomatic)

• Usually found incidentally or on screening
• Persistent cough may be only symptom
• Minor hemoptysis
• Mild dyspnea

Advanced Stage

• Weight loss, anorexia
• Bone pain (metastases)
• Neurologic symptoms (brain mets)
• SVC syndrome, Horner's, hoarseness

Paraneoplastic Syndromes

• SIADH: Hyponatremia (SCLC most common)
• Hypercalcemia: PTHrP production (squamous cell)
• Cushing syndrome: Ectopic ACTH (SCLC)
• Lambert-Eaton: Myasthenic syndrome (SCLC)
• Clubbing: Hypertrophic pulmonary osteoarthropathy
• Dermatomyositis: May precede lung cancer diagnosis

Managing Incidental Lung Findings

• Common scenario: Nodule found on CT for other reason
• Fleischner criteria: Guidelines for incidental nodule follow-up
• Risk stratification: Size, morphology, patient risk factors
• PET-CT: Useful for solid nodules >8mm
• Shared decision-making: Balance risk of cancer vs procedure risk
• Referral: Pulmonology or thoracic surgery for suspicious nodules

Biopsy Methods for Lung Lesions

Bronchoscopy

• Central lesions, endobronchial tumors
• EBUS for mediastinal staging
• Navigational bronchoscopy for peripheral
• Low complication rate

CT-Guided Biopsy

• Peripheral nodules
• High diagnostic yield
• Risk of pneumothorax (~15-25%)
• May not be suitable for all locations

Communicating Risk to Patients

High-Risk Patients

• Emphasize benefit of screening and early detection
• Discuss smoking cessation as priority intervention
• Explain screening process and follow-up
• Address anxiety about findings

Lower-Risk Patients

• Reassure about lower risk
• Encourage symptom awareness
• Promote healthy lifestyle
• Discuss radon testing

Common Patient Questions

I quit smoking years ago. Am I still at risk?

Risk decreases after quitting but never reaches the level of someone who never smoked. Screening may still be recommended if you have significant pack-year history.

What happens if screening finds something?

Most abnormal findings are not cancer. Your doctor may recommend follow-up imaging, PET scan, or biopsy depending on the findings.

Is lung cancer curable?

When caught early, lung cancer can often be cured with surgery. That's why screening high-risk patients is so important.

Key Takeaways

• Leading cause: Lung cancer is the #1 cancer killer - early detection saves lives
• LDCT screening: Recommended for high-risk individuals (age 50-80, ≥20 pack-years)
• Smoking cessation: Most important intervention - offer at every visit
• Shared decision-making: Discuss benefits and harms before screening
• Follow-up: Abnormal findings usually need follow-up imaging, not immediate biopsy

Smoking Cessation Resources

Pharmacotherapy

• Nicotine replacement (patch, gum, lozenge)
• Varenicline (Chantix)
• Bupropion (Wellbutrin)
• Combination therapy most effective

Behavioral Support

• 1-800-QUIT-NOW (national quitline)
• Smokefree.gov resources
• Individual or group counseling
• Mobile apps for quitting

Risk Stratification

Risk Level	Criteria	Recommendation
Very High	≥30 pack-years, age 55-74	Annual LDCT (NLST criteria)
High	≥20 pack-years, age 50-80	Annual LDCT (USPSTF)
Moderate	<20 pack-years or quit >15 yrs	Shared decision-making
Low	Never smoker, no exposures	No screening recommended

Prognostic Factors in Lung Cancer

Favorable

• Early stage (I-II)
• Good performance status
• Targetable mutations (EGFR, ALK)
• High PD-L1 expression
• Adenocarcinoma histology

Unfavorable

• Advanced stage (III-IV)
• Poor performance status
• Small cell histology
• Brain metastases
• Weight loss >5%

Research and Advances

• Liquid biopsy: ctDNA for detection and monitoring
• AI-assisted detection: Machine learning for nodule analysis
• New biomarkers: Research into blood-based screening tests
• Expanded screening criteria: Studies evaluating broader populations
• Risk-based screening: Tailoring screening intervals to individual risk

Key References

NLST Research Team, NEJM 2011

Reduced lung-cancer mortality with low-dose computed tomographic screening.

NELSON Trial, NEJM 2020

Mortality Reduction by Volume CT Screening for Lung Cancer.

USPSTF 2021

Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.

Memory Aids

• "50-80-20-15" - Age 50-80, ≥20 pack-years, quit ≤15 years
• "Pack-years = Packs × Years" - Simple calculation
• "20% mortality reduction" - NLST screening benefit
• "ABCDE" - Age, (smoking) Behavior, COPD, Duration, Exposures

Quick Reference

• Pack-years: Number of cigarette packs smoked per day × years of smoking
• USPSTF criteria: Age 50-80, ≥20 pack-years, currently smoke or quit ≤15 years
• NLST criteria: Age 55-80, ≥30 pack-years, quit ≤15 years
• Screening interval: Annual LDCT
• Stop screening: Age >80, quit >15 years, or limited life expectancy

Healthcare Provider Guidance

Pre-Screening

• Calculate pack-years accurately
• Document smoking history in detail
• Discuss benefits and harms
• Offer smoking cessation
• Ensure informed consent

Post-Screening

• Review results with patient
• Explain Lung-RADS category
• Arrange follow-up as needed
• Continue cessation support
• Schedule annual screening

Screening in Special Populations

• Limited life expectancy: Screen if patient would tolerate treatment
• African Americans: Higher risk at similar exposure levels; may benefit from screening at lower thresholds
• Women: May develop lung cancer with lower smoking exposure
• Prior cancer survivors: Assess second primary risk individually
• Never smokers with exposures: Consider shared decision-making

Quality Measures for LDCT Programs

• Eligibility verification: Accurate assessment of criteria
• Shared decision-making: Documented counseling
• Smoking cessation: Offered and documented
• Lung-RADS reporting: Standardized interpretation
• Follow-up tracking: Systems to ensure timely follow-up
• Quality CT: ACR-accredited facilities preferred

Lung Cancer Risk Calculator Summary

Cause

85% Smoking

Screening

Annual LDCT

Benefit

20% Mortality ↓

Priority

Quit Smoking

Cost-Effectiveness of LDCT Screening

• QALY gain: Estimated $81,000 per QALY (cost-effective by US standards)
• Medicare coverage: LDCT covered for eligible beneficiaries since 2015
• Commercial insurance: Required under ACA with no cost-sharing
• Cost savings: Early detection reduces treatment costs vs late-stage
• Smoking cessation: Adding cessation improves cost-effectiveness

Patient Education Points

• Lung cancer screening is like mammography for breast cancer - catching it early saves lives
• The CT scan uses low radiation and takes just a few minutes
• Most abnormal findings are NOT cancer, but need follow-up
• Quitting smoking is the single best thing you can do for your lungs
• Screening doesn't replace quitting - both are important
• Annual screening is recommended if you remain eligible

Important Reminder

This calculator provides an estimate of lung cancer risk based on established criteria. It is intended for educational purposes and to support shared decision-making conversations between patients and healthcare providers.

Always consult a qualified healthcare professional for personalized medical advice, screening recommendations, and interpretation of results.

Additional Resources

• American Lung Association - lung.org
• American Cancer Society - cancer.org
• National Cancer Institute - cancer.gov
• USPSTF Recommendations - uspreventiveservicestaskforce.org
• Smokefree.gov - resources for quitting smoking
• LungCancerAlliance - lungcanceralliance.org
• Lung Cancer Research Foundation - lungcancerresearchfoundation.org
• GO2 Foundation for Lung Cancer - go2foundation.org
• Bonnie J. Addario Lung Cancer Foundation - lungcancerfoundation.org
• CancerNet - cancer.net/lung-cancer
• Free to Breathe - freetobreathe.org

Need Personalized Risk Assessment?

Get AI-powered analysis and screening recommendations.

👈 START HERE

⬅️Jump in and explore the concept!